Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02331706 · ClinicalTrials.gov registry record · Early Phase 1
IFN-DLI for Relapsed Acute Leukemia After Allo-SCT
A Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT02331706 is a Early Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 16 participants.
The verdict
NCT02331706, a Early Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This trial is designed to determine the feasibility of conventional induction chemotherapy, IFNand G-CSF mobilized DLI (IFN-DLI) in subjects with relapsed AML and ALL after allo-SCT.
Interventions
- DRUG Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-11-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02331706
The ClinicalTrials.gov registry entry for NCT02331706 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily is the first listed.
NCT02331706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02331706 about?
NCT02331706 is a clinical study titled "IFN-DLI for Relapsed Acute Leukemia After Allo-SCT". This trial is designed to determine the feasibility of conventional induction chemotherapy, IFNand G-CSF mobilized DLI (IFN-DLI) in subjects with relapsed AML and ALL after allo-SCT.
What is the current status of trial NCT02331706?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2014-12. Estimated completion is 2017-11-11.
What interventions are being tested in trial NCT02331706?
The interventions under investigation include: Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily (DRUG).
Who is sponsoring clinical trial NCT02331706?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.